We are a clinical-stage pharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Our initial focus is on developing our novel and proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, 5-MeO-DMT) therapies for the treatment of patients with treatment-resistant-depression (TRD).
Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today.
Our portfolio also includes GH002 and GH003, our proprietary intravenous and intranasal 5-MeO-DMT product candidates.
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
GH Research Reports Third Quarter Financial Results and Provides Business Updates
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression